. Author manuscript; available in PMC: 2012 Jul 11.

Published in final edited form as: J Urol. 2008 Dec 18;181(2):512–517. doi: 10.1016/j.juro.2008.10.021

Table 3.

Univariate Proportional Hazards Analyses of Survival

Variable (not adjusted for other factors)	Sample size for each model	Survival Hazard Ratio (95% CI)	p-value
Performance Status: 1 vs. 0	241	1.91 (1.47, 2.49)	<0.0001
Lung Metastases: Yes vs. No	241	0.76 (0.58, 1.00)	0.051
Male vs. Female	241	0.91 (0.69, 1.20)	0.49
Measurable vs. Evaluable Disease	241	1.12 (0.82, 1.52)	0.49
Alkaline Phosphatase⁺:	238	1.42 (1.10, 1.85)	0.008
Calcium⁺:	65	1.18 (0.71, 1.95)	0.53
Hemoglobin⁺:	241	0.73 (0.56, 0.94)	0.015
TSH⁺:	188	1.00 (0.75, 1.34)	0.99
Age⁺:	241	0.92 (0.71, 1.19)	0.54
Weight loss^{+: #}	198	1.26 (0.95, 1.68)	0.11
BUN⁺:	231	1.01 (0.77, 1.31)	0.96
Creatinine⁺:	236	0.94 (0.72, 1.22)	0.64
Progression within first 90 days^*: Yes vs. No	194	2.04 (1.50, 2.79)	<0.0001

Patient must be alive 90 days post-randomization to be included in the analysis

Estimated weight loss in Kg over 6 months

⁺

Hazard ratios compare values above vs. below the median